Tosoh Bioscience announces partnership to improve the purification of viruses
This research project promises to reduce the costs of cell and gene therapy manufacturing processes, making therapies more accessible and cost-effective
13 Jun 2024
Tosoh Bioscience, a leading provider of chromatographic solutions for biomolecule separation and purification, has announced a pioneering partnership with Prof. Dr. Michael Wolff from the University of Applied Sciences Mittelhessen (THM), Gießen, Germany, which will focus on developing continuous purification processes for viruses and viral vectors. This collaboration aligns with Tosoh Bioscience’s efforts to support the cell and gene therapy (CGT) industry and researchers worldwide.
Advancing CGT purification technologies
The goal of this partnership is to improve the purification process of viruses, using Modified Vaccinia virus Ankara (MVA) and Orf viruses as model viruses, as well as adeno-associated virus (AAV) particles. This research project promises to reduce the costs of CGT manufacturing processes, making therapies more accessible and cost-effective. Dr. Carsten-René Arlt, Application Scientist at Tosoh Bioscience, will also support the project with his bioprocess technology expertise.
Prof. Dr. Michael Wolff, commented, "The partnership with Tosoh Bioscience represents a fantastic opportunity to push the boundaries of bioprocessing technology. Together, we aspire to develop a more efficient, continuous chromatographic method for virus and viral vector purification that could greatly enhance the economic viability of CGT manufacturing processes."
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>